Clinical effect of urokinase combined with Zhenfang Baiwanzi in treatment of acute ischemic stroke with syndrome of wind-phlegm blocking collaterals:An analysis of 45 cases
Objective:To investigate the clinical effect of urokinase combined with Zhenfang Baiwanzi in the treat-ment of acute ischemic stroke(AIS)with syndrome of wind-phlegm blocking collaterals.Methods:A total of 90 AIS patients with syndrome of wind-phlegm blocking collaterals were randomly divided into treatment group and control group,with 45 pa-tients in each group.The patients in the control group were given urokinase for intravenous thrombolytic therapy,while those in the treatment group were given Zhenfang Baiwanzi in addition to the treatment in the control group;the course of treatment was 14 days for both groups.The two groups were compared in terms of National Institutes of Health Stroke Scale(NIHSS)score,modified Rankin Scale(mRS)score,traditional Chinese medicine(TCM)syndrome score,plasma fibrinogen(FIB),and D-dimer(D-D).Overall response was evaluated,and adverse reactions were recorded.Results:There was a significant difference in overall response rate between the treatment group and the control group[93.33％(42/45)vs 84.44％(38/45),P＜0.05].After treatment,both groups had significant reductions in NIHSS score,mRS score,TCM syndrome score,FIB,and D-D,and the treatment group had significantly greater reductions than the control group(P＜0.05).There was no significant difference in the incidence rate of adverse events between the treatment group and the control group[6.66％(3/45)vs 11.10％(5/45),P＞0.05].Conclusion:Urokinase combined with Zhenfang Baiwanzi has a good clinical effect in the treatment of AIS patients with syndrome of wind-phlegm blocking collaterals and can promote the recovery of neurological function and reduce the levels of FIB and D-D,with a favorable safety profile.
acute ischemic strokesyndrome of wind-phlegm blocking collateralsZhenfang Baiwanziurokinase
万方数据
维普
